High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

被引:0
作者
J Boultwood
J Perry
R Zaman
C Fernandez-Santamaria
T Littlewood
R Kusec
A Pellagatti
L Wang
R E Clark
J S Wainscoat
机构
[1] LRF Molecular Haematology Unit,Department of Clinical Sciences, Department of Haematology
[2] NDCLS,University Department of Haematology
[3] University of Oxford,undefined
[4] John Radcliffe Hospital,undefined
[5] University Hospital Merkur,undefined
[6] Royal Liverpool University Hospital,undefined
来源
Leukemia | 2010年 / 24卷
关键词
CML; SNP array analysis; UPD; gene;
D O I
暂无
中图分类号
学科分类号
摘要
We have undertaken a genome-wide single nucleotide polymorphism (SNP) array analysis of 41 chronic myeloid leukemia (CML) patients. In total, 44 regions of uniparental disomy (UPD) >3 Mb were identified in 24 of 32 patients in chronic phase (CP), and 21 regions of UPD >3 Mb were identified in 13 of 21 patients in blast crisis (BC). Chromosome 8 had the highest frequency of UPD regions in both CP and BC samples. Eight recurrent regions of UPD were observed among the 41 patients, with chromosome 8 showing the highest frequency. Ten regions of copy number change (CNC) >3 Mb were observed in 4 of 21 patients in BC, whereas none were observed in CP. We have identified several recurrent regions of UPD and CNC in CML that may be of pathogenetic importance. Overrepresentation of genomic aberrations (UPD and copy number gain) mapping to chromosome 8 was observed. Selected candidate genes mapping within the aberrant genomic regions were sequenced and mutation of the TP53 gene was observed in one case in BC and of the ASXL1 gene in 6 of 41 cases in CP or BC. Mutation of ASXL1 represents an important new molecular abnormality in CML.
引用
收藏
页码:1139 / 1145
页数:6
相关论文
共 216 条
[1]  
Rowley JD(1973)Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 290-293
[2]  
Shet AS(2002)Chronic myelogenous leukemia: mechanisms underlying disease progression Leukemia 16 1402-1411
[3]  
Jahagirdar BN(2003)Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 1423-1432
[4]  
Verfaillie CM(2009)Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 1054-1061
[5]  
Hughes TP(2001)Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 1038-1042
[6]  
Kaeda J(2009)Imatinib resistance in CML Cancer Lett 274 1-9
[7]  
Branford S(2002)Cytogenetic and molecular genetic evolution of chronic myeloid leukemia Acta Haematol 107 76-94
[8]  
Rudzki Z(2000)Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase Blood 96 358-361
[9]  
Hochhaus A(2006)hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia Leukemia 20 671-679
[10]  
Hensley ML(1989)Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia Proc Natl Acad Sci USA 86 6783-6787